Oral Mucositis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Oral Mucositis Clinical Trial Report Overview
A total of 506 Oral Mucositis clinical trials were conducted as of December 2023. The Oral Mucositis clinical trial report provides a comprehensive understanding of the Oral Mucositis clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials.
Key Regions | · Asia-Pacific
· Europe · North America · Middle East and Africa · South and Central America |
Key Countries | · Iran
· United States · China · Japan · India · United Kingdom · Germany |
Key Sponsor Types | · Company
· Institution · Government |
Leading Sponsors | · Amgen Inc
· Swedish Orphan Biovitrum AB · Galera Therapeutics Inc · Alizyme plc (Inactive) · GSK plc · Mallinckrodt Plc · Jazz Pharmaceuticals Plc · Novartis AG · Others |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Oral Mucositis Clinical Trials Segmentation by Regions and Countries
Asia-Pacific led the Oral Mucositis clinical trials landscape with more than 30% of the clinical trials conducted as of December 2023.
The key regions considered for Oral Mucositis clinical trials analysis are Asia-Pacific, Europe, North America, the Middle East and Africa, and South and Central America.
In the country-wise analysis, Iran and the US had the highest number of oral mucositis clinical trials, as of December 2023. China had the highest average patient enrollment of oral mucositis clinical trials, as of December 2023.
G7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, Japan accounted for the highest proportion of Oral Mucositis to Gastrointestinal clinical trials as of December 2023.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Brazil accounted for the highest proportion of Oral Mucositis to Gastrointestinal clinical trials as of December 2023.
Oral Mucositis Clinical Trials Analysis by Regions, 2023 (%)
Buy the Full Report for More Regional Insights into the Oral Mucositis Clinical Trials
Oral Mucositis Clinical Trials Segmentation by Sponsor Types
The key sponsor types for Oral Mucositis clinical trials are company, institution, and the government. As of December 2023, more than 67% of Oral Mucositis clinical trials conducted were sponsored by institution sponsor type, followed by the company.
Oral Mucositis Clinical Trials Analysis by Sponsor Type, 2023 (%)
Buy the Full Report for More Insights into the Oral Mucositis Clinical Trials Sponsor Types
Oral Mucositis Clinical Trials - Competitive Landscape
In 2023, Amgen Inc conducted the highest number of Oral Mucositis clinical trials.
A few of the leading sponsors for Oral Mucositis clinical trials are:
- Amgen Inc
- Swedish Orphan Biovitrum AB
- Galera Therapeutics Inc
- Alizyme plc (Inactive)
- GSK plc
- Mallinckrodt Plc
- Jazz Pharmaceuticals Plc
- Novartis AG
Oral Mucositis Clinical Trials Analysis by Leading Companies, 2023 (%)
Buy Full Report to Know More About the Leading Players of Oral Mucositis Clinical Trials
Segments Covered in the Report
Oral Mucositis Clinical Trials Regional Outlook (2023)
- Asia-Pacific
- Europe
- North America
- Middle East and Africa
- South and Central America
Oral Mucositis Clinical Trials Country Outlook (2023)
- Iran
- United States
- China
- Japan
- India
- United Kingdom
- Germany
Oral Mucositis Clinical Trials Sponsor Type Outlook (2023)
- Company
- Institution
- Government
Scope
- The report provides a snapshot of the global clinical trials landscape.
- The report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status.
- The report reviews the top companies involved and enlists all trials (trial title, phase, and status) of the company.
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with a reason for accomplishment.
- The report provides enrollment trends for the past five years.
- The report provides the latest news for the past three months.
Reasons to Buy
- Assists in formulating key investment strategies.
- Helps in identifying time-saving and cost-efficient locations to conduct clinical trials.
- Provides top-level analysis of the global clinical trials market to help in identifying key business opportunities.
- Helps in understanding trial count and enrollment trends by country in the global therapeutics market.
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
- Facilitates clinical trial assessment of the indication on a global, regional, and country level.
Swedish Orphan Biovitrum AB
Galera Therapeutics Inc
Alizyme plc (Inactive)
GSK plc
Mallinckrodt Plc
Jazz Pharmaceuticals Plc
Novartis AG
Patient Square Capital LP
Solasia Pharma KK
Table of Contents
Table
Figures
Frequently asked questions
-
Which region accounted for the highest number of Oral Mucositis clinical trials in December 2023?
Asia-Pacific accounted for the highest number of Oral Mucositis clinical trials as of December 2023.
-
Which country conducted the highest number of Oral Mucositis clinical trials?
Iran and the US conducted the highest number of Oral Mucositis clinical trials as of December 2023.
-
Which sponsor type was the most prominent in the Oral Mucositis clinical trials?
As of December 2023, most of the Oral Mucositis clinical trials conducted were sponsored by institution sponsor type.
-
Who are the leading sponsors of Oral Mucositis clinical trials?
A few of the leading sponsors of Oral Mucositis clinical trials are Amgen Inc, Swedish Orphan Biovitrum AB, Galera Therapeutics Inc, Alizyme plc (Inactive), GSK plc, Mallinckrodt Plc, Jazz Pharmaceuticals Plc, and Novartis AG among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.